Sofinnova Partners backs European life sciences sector with €725M raise
European venture capital (VC) giant, Sofinnova Partners, has closed a €725m ($815m) fund to support a range of life sciences…
European venture capital (VC) giant, Sofinnova Partners, has closed a €725m ($815m) fund to support a range of life sciences…
The US Food and Drug Administration (FDA) has approved AstraZeneca's Imfinzi (durvalumab) in combination with Padcev (enfortumab vedotin) for adult patients with muscle-invasive bladder cancer (MIBC) who cannot receive or have…
The US Food and Drug Administration (FDA) has declined to approve Summit Therapeutics’ biologics licence application (BLA) for ivonescimab in patients with locally advanced or metastatic non-small cell lung cancer…
Following the US midterm elections, Arizona Senator Mark Kelly used day one of HLTH 2026 in Las Vegas to set out the Democrats' emerging healthcare priorities, against a backdrop of…
The US Food and Drug Administration (FDA) appears to have quietly paused the Commissioner’s National Priority Voucher (CNPV) pilot programme, a controversial expedited review framework established by former agency chief…
Swiss biotech company Neurosterix has banked $105m in a Series B funding round to push its range of neuropsychiatric candidates further down the pipeline. The financing, which was led by…
Bristol Myers Squibb (BMS) is set to merge its separate research and development (R&D) departments into a single entity, effective from 1 January 2027. The company’s executive vice president and…